Someone knew at end of close of Friday. Hence the drop. My guess is this is a non event except opening. Will close up at end of day Monday along with all others. Undervalued at this price range. Sell $106
How low will it go today?
Kirk also owns a large position in Ziopharm Oncology, Inc. (ZIOP). Ziopharm is employing novel gene expression and control technology to deliver DNA for the treatment of cancer. Its technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System platform to turn on and off, and modulate gene expression at the cancer site in order to improve the therapeutic index.
Last March, the company experienced a significant setback when its lead drug Palifosfamide, failed to show any statistically significant improvement in progression free survival in soft tissue sarcoma. However, Ziopharm seems to be back on track with its Ad-RTS-IL-12, which is a novel DNA-based therapeutic candidate that is being evaluated with the oral activator veledimex, in patients with advanced melanoma.
In December of last year, Ziopharm reported positive interim results from the ongoing Phase 1/2 melanoma study which showed good safety and tolerability. Additionally, in December of last year Ziopharm initiated a Phase 1 study of Ad-RTS-IL-12 in subjects with recurrent or progressive glioblastoma or grade III malignant glioma (brain cancer).
Fellow Seeking Alpha contributor "Chemistfrog" explains this treatment in an article from June, 2013;
Ad-RTS IL-12, employs the use of an adenoviral vector to deliver into patients' cells the IL-12 DNA plasmid instructing the cells to produce the IL-12 cytokine.
Interleukin-12 is a protein (cytokine) known to trigger an immune response to cancer.
Cyotines are very important in the immune system as they modulate the balance between humoral and cell-based immune responses, and they regulate the maturation, growth, and responsiveness of particular cell populations.
Interestingly enough, Ziopharm licenses Ad-RTS IL-12 from Intrexon, Kirk's largest investment to date. If Ad-RTS IL-12 ultimately proves to be a success, Kirk will be rolling in the money in a big way.
Kirk's Third Security LLC owns 17,815,708 shares of Ziopharm, which represents a
Jnj going to drop big tomorrow. Lots of calls were bought.
Jnj priced options on this deal and now the deal is a no go. What happened?
Has an agreement but undervalued.
Which would you rather own?
Until that point Gild is making a killing but gets no respect as the King. Too many Jesters trying to fool it down. Until anything happens besides speculation trade the range from $99 to $104. If you want a smart trade buy JNJ. Breaking out of its lows and oversold.
Ziopharm Oncology (ZIOP - Get Report) , a biotechnology company, rallied $1.28 to $11.78 on Thursday, continuing its late run from Wednesday. The stock's pattern looks like an accelerating, rising flag that could explode toward $14.50 to $15, our short-term target.
No one cares on earnings it is expected earnings or the potential which will push this stock higher.
Every day the analysts screamed over valued and a top is on hand. Apple just about doubled by April. If you played the cheap calls $17k made you millions in less than 30 days. Apple price target undervalued because it is now the largest company. It will still double from $90 to $180! with its product line. Let the shorts buy their shares higher. Let the analysts be all wrong. Carl is the best analyst because he has personal skin in the game. Who you going to believe with your money? I am banking on I Carl!
Long and strong thousands of upside apple calls.
Should of been over $125 after earnings. All this BS about price wars cutting into profits. Like comparing apples and oranges. Lots of fruit to go around but more people drink orange juice than apple in the morning! In India they will be drinking just orange juice! Not an apple to be seen!
Mean while next earnings should be great! Buy the dips and ignore the flips.
Will test $105 next few days.
We are $20 undervalued at this level. With the great earnings behind us and racing past the high end of expectations next earnings will make up for this last earnings.
Can't stop until I get enough!
bought a ton of the $103 calls next week. Look what happened to apple last week from $119 to $127 by friday. $121 calls at beginning of week $.40. I think it is going to at least $105. Also I bought a ton of apple $128 calls for next week as well. Market breaking out!
At some point will close over $107 and fireworks on buying will begin.
I am a buyer at this price.